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Cisplatin and carboplatin result in similar
gonadotoxicity in immature human testis
with implications for fertility preservation in
childhood cancer
Melissa D. Tharmalingam1,2†, Gabriele Matilionyte1†, William H. B. Wallace3, Jan-Bernd Stukenborg4,
Kirsi Jahnukainen4,5, Elizabeth Oliver4, Anne Goriely6, Sheila Lane7, Jingtao Guo8,9, Bradley Cairns9,
Anne Jorgensen10, Caroline M. Allen11, Federica Lopes1, Richard A. Anderson1, Norah Spears11 and
Rod T. Mitchell1,3*
Abstract
Background: Clinical studies indicate chemotherapy agents used in childhood cancer treatment regimens may
impact future fertility. However, effects of individual agents on prepubertal human testis, necessary to identify later
risk, have not been determined. The study aimed to investigate the impact of cisplatin, commonly used in
childhood cancer, on immature (foetal and prepubertal) human testicular tissues. Comparison was made with
carboplatin, which is used as an alternative to cisplatin in order to reduce toxicity in healthy tissues.
Methods: We developed an organotypic culture system combined with xenografting to determine the effect of
clinically-relevant exposure to platinum-based chemotherapeutics on human testis. Human foetal and prepubertal
testicular tissues were cultured and exposed to cisplatin, carboplatin or vehicle for 24 h, followed by 24–240 h in
culture or long-term xenografting. Survival, proliferation and apoptosis of prepubertal germ stem cell populations
(gonocytes and spermatogonia), critical for sperm production in adulthood, were quantified.
Results: Cisplatin exposure resulted in a significant reduction in the total number of germ cells (− 44%, p < 0.0001)
in human foetal testis, which involved an initial loss of gonocytes followed by a significant reduction in
spermatogonia. This coincided with a reduction (− 70%, p < 0.05) in germ cell proliferation. Cisplatin exposure
resulted in similar effects on total germ cell number (including spermatogonial stem cells) in prepubertal human
testicular tissues, demonstrating direct relevance to childhood cancer patients. Xenografting of cisplatin-exposed
human foetal testicular tissue demonstrated that germ cell loss (− 42%, p < 0.01) persisted at 12 weeks. Comparison
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between exposures to human-relevant concentrations of cisplatin and carboplatin revealed a very similar degree of
germ cell loss at 240 h post-exposure.
Conclusions: This is the first demonstration of direct effects of chemotherapy exposure on germ cell populations in
human foetal and prepubertal testis, demonstrating platinum-induced loss of all germ cell populations, and similar
effects of cisplatin or carboplatin. Furthermore, these experimental approaches can be used to determine the
effects of established and novel cancer therapies on the developing testis that will inform fertility counselling and
development of strategies to preserve fertility in children with cancer.
Keywords: Human, Testis, Cisplatin, Germ cell, Fertility, Prepubertal, Foetal, Xenograft
Background
Survival rates for children with cancer have increased
dramatically over recent decades, and currently, more
than 80% of those affected are expected to survive their
disease into adulthood [1]. However, the long-term im-
pacts of cancer treatment remain a major concern for
this patient population. The mainstay of cancer treat-
ment includes chemotherapy and radiotherapy, both of
which have the potential to damage healthy tissues
resulting in significant long-term morbidity [2]. An asso-
ciation between chemotherapy exposure and effects on
the reproductive system in male and female childhood
cancer survivors is well-recognised and this may result
in infertility in adulthood [3, 4]. Alkylating agents (e.g.
cyclophosphamide and procarbazine) are reported to be
amongst the most highly gonadotoxic chemotherapeutic
compounds in both males and females, and cumulative
exposure to these agents can be used to estimate the risk
of gonadal damage in patients due to receive such ther-
apies [5]. However, these models do not include non-
alkylating agents that may also contribute to gonadotoxi-
city, nor are they able to determine the direct effects of
chemotherapeutic agents on the gonad.
Major differences exist between the prepubertal and
adult testis in humans, especially in terms of germ cell
populations [6]. Spermatogenesis does not start until
after puberty and therefore sperm are not present. The
germ cell populations in the prepubertal testis are pre-
dominantly spermatogonia, expressing MAGEA4 pro-
tein. This includes a sub-population of spermatogonial
stem cells (SSC), which express UTF1 [7, 8]. In human
foetal and infantile testis, an additional population of un-
differentiated germ cells (gonocytes), which express
AP2γ, are present. Gonocytes differentiate into (pre)-
spermatogonia over the course of foetal and early post-
natal life [6]. Therefore, future fertility is dependent on
differentiation from gonocyte to spermatogonia in in-
fancy and subsequent survival of the SSC population
during childhood.
Platinum-based chemotherapeutic drugs are widely
used in paediatric oncology for the treatment of solid tu-
mours including neuroblastoma, germ cell tumours and
osteosarcoma [5, 9, 10]. These agents are considered to
be cell-cycle independent and act to form DNA adducts,
which elicit apoptosis and cell death [11]. Cisplatin is
the most frequently used platinum-based compound,
whilst carboplatin may be used as an alternative to cis-
platin as it is considered to have a lower risk of ototox-
icity and nephrotoxicity [12], although relative
gonadotoxicity remains to be determined.
No previous studies have been conducted to test the
effects of platinum-based chemotherapy on human tes-
ticular tissues. However, experimental systems have re-
cently been developed to assess the direct impact of
pharmaceuticals on immature human testicular tissues
including short- (in vitro) and long-term (testicular
xenograft) effects of acute exposure [13, 14]. These ex-
perimental approaches utilise human foetal testis, which
contain the major germ cell populations of the child-
hood testis (gonocytes and spermatogonia), and can
therefore be used to model the acute effects of chemo-
therapy exposure and potential for recovery of immature
human testicular tissue.
In the present study, we aimed to determine the effects
of exposure to clinically-relevant concentrations of
platinum-based chemotherapy on germ cells of the im-
mature prepubertal human testis using human foetal
and prepubertal tissues. We also aimed to investigate the
relative gonadotoxicity of cisplatin compared to that of
carboplatin.
Methods
Experimental design
Given that childhood cancer survivors are reported to
have lower fertility rates in adulthood, we aimed to
understand the effects of exposure to platinum-based
chemotherapy agents (cisplatin and carboplatin) on key
germ cell populations in immature human testis. We
performed controlled laboratory experiments using both
in vitro (short-term) and xenograft (long-term) models
(Fig. 1). Experimental protocols were designed prior start
of experiments. Immature human testicular tissue pieces
were exposed to clinically relevant chemotherapy doses
based on human plasma serum levels obtained from
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paediatric cancer patients. Sample size was determined
based on previous studies using human tissue (at least
n = 5 for each experiment).
Initial experiments using human foetal tissues investi-
gated the effects of cisplatin-exposure on germ cells
using two drug concentrations (0.5 and 1.0 μg/ml) and
two time-points post-exposure (24 and 96 h). Further ex-
periments were performed to determine the germ cell
effects of cisplatin-exposure (0.5 μg/ml only) at inter-
mediate (72 h) and long-term (240 h) time-points. Some
of the in vitro cultured tissue pieces were randomly se-
lected at 24 h post-exposure and subsequently xeno-
grafted for 12 weeks. Reciprocal grafts of control- or
cisplatin-exposed tissue were grafted into the right and
left dorsal flank of the same mouse, respectively. In
addition, a comparison between exposure to cisplatin
(0.5 μg/ml) and therapeutic equivalent concentrations of
carboplatin (5 μg/ml) was investigated at 72 and 240 h
post-exposure. Due to the limited amount of available
tissue, the effects of cisplatin-exposure on germ cells in
prepubertal human testicular tissue were investigated
using a single concentration of cisplatin (0.5 μg/ml) at
two time-points post-exposure (24 and 96 h).
All data were analysed once the study was completed
and no outliers were excluded. To compare the effect of
treatment versus vehicle controls, we analysed at least
two tissue sections from two replicates for each treat-
ment. Endpoints included the quantification of key germ
cell populations and assessment of proliferation and
apoptosis. Investigators performing the quantification
were blinded to the treatment group.
Study approval
Ethical approval for use of human foetal tissues for re-
search was obtained from the South East Scotland Re-
search Ethics Committee (LREC08/S1101/1), NRES
committee North East – Newcastle and North Tyneside
1 (08/H0906/21+5) and NRES Committee London –
Fig. 1 Overview of experimental setup. Designed using BioRender.com. Abbreviations: VEH, vehicle; 0.5 CIS, cisplatin (0.5 μg/ml); 1.0 CIS, cisplatin
(1.0 μg/ml); CARBO, carboplatin (5 μg/ml)
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Fulham (18/10/0822), and written informed consent was
given by the women. Ethical approval for collection and
use of human prepubertal testis tissues in research was
obtained from the South East Scotland Research Ethics
Committee (13/SS0145) and Oxford University Hospitals
NHS Foundation Trust (2016/0140). Written informed
consent was obtained from patients’ parents/guardians
and/or the patient themselves (where appropriate).
For studies involving animals, specific approval, in-
cluding ethical approval, was given by the UK Home Of-
fice. All procedures carried out were by the University of
Edinburgh Bioresearch and Veterinary Services and per-
formed in accordance with the Animal (Scientific proce-
dures) Act 1986.
Tissue collection
Human foetal testicular tissues
Testes from second-trimester human foetuses (14–22
weeks gestation; total n = 33) were obtained after med-
ical and surgical termination of pregnancy as described
previously [6]. None of the terminations were due to
foetal abnormalities. Ultrasound scan and subsequent
direct measurement of foot length were used to deter-
mine gestational age. Sex was determined by PCR for
the male-specific gene SRY.
For studies involving animals, specific approval, in-
cluding ethical approval, was given by the UK Home Of-
fice and all procedures carried out were in accordance
with the Animal (Scientific procedures) Act 1986.
Prepubertal human testicular tissues
Prepubertal testicular tissues (n = 5 patients; aged 1, 1, 8,
11 and 12 years) were obtained from chemotherapy-
naïve patients undergoing a testicular biopsy for fertility
preservation at the Royal Hospital for Sick Children in
Edinburgh and John Radcliffe Hospital in Oxford. A
small portion (~ 10%) of the biopsy was donated for re-
search purposes. Testicular tissues from Edinburgh were
collected and immediately transported in Nutristem®
hSEC XF Medium (Biological industries) supplemented
with 1% penicillin/streptomycin (Sigma-Aldrich). Tes-
ticular biopsies from Oxford were transported overnight
in Hank’s Balanced Salt solution (HBSS) with 10% hu-
man serum albumin.
Hanging drop culture system
Human foetal and prepubertal tissue was utilised for
in vitro experiments in a hanging drop culture system
[15]. Testicular tissue was cut into small pieces (~ 1
mm3) and placed into 30 μl droplets of appropriate
media (for foetal tissue: Alpha MEM (Lonza); 10% foetal
bovine serum, 1% penicillin/streptomycin, 1% non-
essential amino acids, 2 mM L-glutamine, 2 mM sodium
pyruvate and 1% insulin transferrin selenium (ITS) (all
Sigma-Aldrich); for prepubertal tissue: Alpha MEM
(Lonza) and 10% Knockout Serum Replacement (KSR;
Gibco)) and cultured at 37 °C and 32 °C, respectively,
under 5% CO2. Tissue pieces were cultured for 1–3 days
(subject to the exact timing of the tissue arrival) prior to
exposure to cisplatin (Sigma-Aldrich) or vehicle control
(ddH2O) for 24 h. Tissue pieces were then transferred to
fresh media without cisplatin and cultured until 24, 72,
96 and 240 h post-cisplatin exposure. In a separate set of
culture experiments, tissues were exposed for 24 h to ei-
ther cisplatin (0.5 μg/ml), carboplatin (5 μg/ml; Calbio-
chem) or vehicle control (ddH2O) for 24 h and the
experiment was ended at 72 and 240 h post-exposure. In
some cases, there was sufficient material from a biopsy
sample to allocate to more than one experimental setup.
Human tissue xenografting
Testicular tissue pieces from human foetuses (n = 4) that
were cultured in vitro were used for xenografting at 24 h
post-cisplatin or vehicle exposure. As previously de-
scribed [16], tissue fragments were grafted subcutane-
ously into host adult CD1-nude mice using a 13-gauge
cancer implant needle (Popper and Sons). For each
foetal sample, a total of 4 pieces (~ 1 mm3) of testicular
tissue was inserted under the dorsal skin of the host
mouse, with random allocation of two vehicle controls
and two 0.5 μg/ml cisplatin-treated pieces along either
side of the midline. A total of 4 mice were grafted per
foetal sample, and the mice were maintained for 12
weeks post grafting before retrieval of the tissue. Mice
were housed in the same location and exposed to 12 h
light/dark cycles and room temperature, ~ 20–25 °C.
Mice were administered 100 μl of 20 IU human chori-
onic gonadotrophin (hCG) (Ovitrelle, Merck Serono) be-
ginning a week after xenografting which was continued
three times a week until the end of the experiment. One
mouse was culled before the end of the experiment due
to poor health and was not included in the analysis. For
xenograft retrieval, host mice were culled by inhalation
of CO2 and cervical dislocation. Weight of host mouse
body and retrieved grafts were recorded.
Tissue processing
At the end of each experiment, tissue pieces were fixed
in Bouin’s fluid (Clin-Tech) for 1 h and transferred to
70% ethanol. Post fixation, samples were paraffin-
embedded, 5 μm sectioned and assessed by H&E using
standard protocol or used for immunohistochemistry as
described below. Only samples that showed healthy tis-
sue morphology (defined tubules, minimal apoptosis and
germ cell presence) in pre-culture and vehicle controls
were included in the analyses. Two sections from two
replicates for each treatment were stained and analysed.
Tharmalingam et al. BMC Medicine          (2020) 18:374 Page 4 of 16
Immunohistochemistry
Double colourimetric immunohistochemistry was per-
formed to detect gonocytes and spermatogonia (details
of primary antibody in Additional File 1: Table S1).
Sections were dewaxed by incubating in xylene (BDH
Prolabo®, VWR Chemicals) twice for 5min each. Tissue
slides were rehydrated in alcohol series (100% twice, 95%,
80% and 70%) for 20 s and thoroughly rinsed in tap water.
Heat-induced epitope retrieval of all slides was carried out
in a pressure cooker containing 0.01M citrate buffer. Tis-
sue sections were rinsed in water and blocked with 3% (v/
v) hydrogen peroxide in methanol for 15min on a rocker
at room temperature. To minimise cross-reactivity, tissue
sections were incubated with blocking agent (consisting of
20% appropriate animal serum in Tris-buffered saline
(TBS, 0.01M Tris, 0.85% sodium chloride, pH 7.4) and 5 g
of bovine serum albumin (BSA, Sigma-Aldrich, GmbH))
for 30min at room temperature. Primary antibody diluted
in blocking agent was added to tissue sections for over-
night incubation at 4 °C.
To detect the primary antibody, slides were incubated
with peroxidase (ImmPRESS, Vector Laboratories) for
30 min at room temperature. Each incubation step was
followed by two 5-min washes in TBS. To visualise the
first antibody, 3,3-diaminobenzidine (DAB, Vector La-
boratories) was added and colour development (usually
up to 3 min) was monitored microscopically and stopped
by washing in deionised water. Prior to the second anti-
body detection, antigen epitopes were retrieved by pla-
cing slides in pre-heated 0.01M citrate buffer and
boiling for 2.5 min using a microwave. Once cooled,
slides were blocked with appropriate normal serum/
TBS/BSA for 30 min at room temperature, followed by
an overnight incubation at 4 °C with subsequent primary
antibody diluted in normal serum/TBS/BSA.
To detect the second antibody, tissue sections were in-
cubated with alkaline phosphatase (ImmPRESS, Vector
Laboratories) for 30 min at room temperature, visualised
by adding FastBlue substrate (Vector Laboratories), and
the reaction was stopped by rinsing in deionised water.
Slides were mounted with PermaFluor aqueous medium
(Lab Vision™, Thermo Scientific). Images were taken on
Axio Scan.Z1 slide scanner (Carl Zeiss Microscopy,
GmbH) at × 20 magnification.
In addition, each experiment involved positive (all re-
agents added) and negative controls (primary antibody
replaced with blocking agent) of pre-culture controls
from each foetal sample. Slides for different treatments
of the same foetal sample were all processed in parallel
in a single experiment.
Immunofluorescence
Dewaxing, rehydration, antigen retrieval and blocking of
endogenous peroxidase and appropriate serum blocking
were performed as described above for immunohisto-
chemistry. To detect the primary antibody, slides were
incubated with peroxidase-conjugated secondary anti-
body for 30 min and visualised using Tyramide signal
amplification kit (PerkinElmer, Inc.) at 1:50 for 10 min
(both steps at room temperature). Antigen retrieval was
performed using microwave treatment prior to adding
subsequent primary antibodies. Same detection steps
using different fluorophores were performed for each
primary antibody. Nuclei were counterstained with
Hoechst (Thermo Fisher Scientific) diluted in TBS at 1:
2000. Tissue sections were mounted with Permafluor
(Lab Vision™, Thermo Scientific), and tiled images of the
whole tissue section were captured at × 20 magnification
using LSM 780 Confocal microscope (Carl Zeiss Micros-
copy, GmbH). Primary and secondary antibody details
used for single and triple immunofluorescent staining
are in Additional File 1: Table S1.
Statistics
Positively stained cells were manually counted and tubu-
lar, and tissue areas were measured using Zen 2.3 lite
Blue Edition (Carl Zeiss Microscopy, GmbH) software.
The interstitial area was obtained by subtracting the
tubular area from the tissue area. All tubules per tissue
section were included in the analysis. Cell numbers per
tubular or tissue area (mm2) were calculated and plotted.
Percentage in cell number in comparison to control was
also calculated. Data were presented as mean +/− SEM.
Two-way ANOVA statistical analysis was performed in
order to account for inter-individual sample variation
using GraphPad Prism 8 software (La Jolla, CA, USA).
Statistical significance was set to p < 0.05.
Single-cell sequencing analysis
Single-cell RNA sequencing was previously performed
on human prepubertal testis ranging from 1 to 11 years
of age [7]. The resulting dataset was interrogated to de-
fine the cell states and populations present in the testis
of a 7-year-old, whilst MAGEA4 (spermatogonia) and
UTF1 (SSCs) expression was extracted from the dataset
for individuals aged 1, 7 and 11 years. Data were pre-
sented as t-SNE and violin plots.
Results
Cisplatin exposure results in differential germ cell loss in
human foetal testis
Human foetal testicular tissues (n = 11, 14–22 GW)
were exposed in vitro to cisplatin (0.5 and 1.0 μg/ml)
or vehicle for 24 h, and germ cells per tubular area
(mm2) were quantified at 24 and 96 h post-exposure
(Fig. 2). Germ cell populations consisted of gonocytes
(AP2γ+) and (pre)spermatogonia (MAGEA4+)
(Fig. 2a–c). At 24 h post-exposure, there was no
Tharmalingam et al. BMC Medicine          (2020) 18:374 Page 5 of 16
significant difference in either germ cell population in
cisplatin-exposed compared to vehicle-exposed tes-
ticular tissues (Fig. 2d–f). However, at 96 h post-
exposure, germ cell loss was evident for cisplatin ex-
posure at both concentrations (Fig. 2g–i). Quantifica-
tion showed that both germ cell populations
(gonocytes and (pre)spermatogonia) were significantly
reduced in cisplatin-exposed testicular tissues (Fig. 2j,
k) and overall total germ cell number (gonocytes +
(pre)spermatogonia) was reduced by 44% for both
0.5 μg/ml (301 v 536, p < 0.0001) and 1.0 μg/ml (298 v
536, p < 0.0001) cisplatin exposures (Fig. 2l). Since the
degree of germ cell loss was similar with both con-
centrations of cisplatin, further experiments were fo-
cused on exposure to 0.5 μg/ml cisplatin only.
In order to determine the timing of germ cell loss
for gonocytes and (pre)spermatogonia, we investigated
the effect of cisplatin exposure at an intermediate
Fig. 2 Acute effects of cisplatin exposure on germ cell populations in the human foetal testis. AP2γ+ gonocytes (brown) and MAGEA4+
(pre)spermatogonia (blue) protein expression in the human foetal testis 24 h (a–c) and 96 h (g–i) following exposure to vehicle or cisplatin (0.5
and 1.0 μg/ml). Scale bars represent 100 μm (or 50 μm for insets). Dotted lines outline seminiferous tubules. Quantification of germ cell counts per
tubular area (mm2) in the human foetal testicular tissues 24 h (d–f) and 96 h (j–l) following exposure to vehicle (VEH) or cisplatin (0.5 and 1.0 μg/
ml). Germ cell numbers were unaffected 24 h post-exposure, whilst a significant reduction in number of gonocytes, (pre)spermatogonia and total
germ cells was observed at 96 h following exposure to 0.5 μg/ml and 1.0 μg/ml cisplatin exposure. Data analysed using two-way ANOVA. **p <
0.01, ***p < 0.001 and ****p < 0.0001. Values shown are means ± SEM and each data point represents an individual foetus (n = 9–11)
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time-point (72 h post-exposure, n = 8; Fig. 3a–e).
There was a significant reduction in the number of
gonocytes in cisplatin-exposed testicular tissues (−
21%, 380 v 479, p < 0.01; Fig. 3c). However, (pre)sper-
matogonial number was unchanged in cisplatin-
exposed testicular tissues compared with vehicle con-
trol (270 v 281, p > 0.05; Fig. 3d). Despite the fact
that (pre)spermatogonial number was not affected by
cisplatin exposure, the loss of gonocytes was sufficient
to cause a significant overall reduction in total germ
cell number (− 15%, 650 v 763, p < 0.01; Fig. 3e).
Progression of cisplatin-induced germ cell loss was in-
vestigated in testicular tissues at 240 h post cisplatin-
exposure (n = 14; Fig. 3f–j). The reduction in gonocyte
(− 41%, 194 v 327, p < 0.0001; Fig. 3h), (pre)spermatogo-
nia (− 18%, 324 v 393, p < 0.01; Fig. 3i) and total germ
cell number (− 37%, 433 v 691, p < 0.0001; Fig. 3j) was
maintained over the extended culture period.
Fig. 3 Intermediate and prolonged effects of cisplatin exposure on germ cell populations in the human foetal testis. AP2γ+ gonocytes (brown)
and MAGEA4+ (pre)spermatogonia (blue) protein expression in the human foetal testis 72 h (a, b) and 240 h (f, g) following exposure to vehicle
or cisplatin (0.5 μg/ml). Scale bars represent 100 μm (or 50 μm for insets). Dotted lines outline seminiferous tubules. Quantification of germ cell
subpopulations in the human foetal testis 72 h (c–e) and 240 h (h–j) following exposure to vehicle (VEH) and cisplatin (CIS; 0.5 μg/ml). At 72 h
post-exposure to cisplatin, gonocytes and total germ cells were significantly reduced, whilst (pre)spermatogonia were unaffected. At 240 h post-
exposure, a decrease in all germ cell populations was observed. Data analysed using two-way ANOVA. *p < 0.05, **p < 0.01 and ****p < 0.0001.
Values shown are means ± SEM and each set of data points represents an individual foetus (n = 8–14)
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Cisplatin exposure reduces cell proliferation in both germ
cell populations in human foetal testis
To investigate further the reason for germ cell loss in
cisplatin-exposed testicular tissues, we assessed apoptosis
by immunostaining for cleaved caspase 3 (CC3) (Add-
itional File 2: Figure S2). There was no significant difference
in total number of apoptotic (CC3+) cells in the seminifer-
ous cords of cisplatin-exposed testicular tissues, compared
to vehicle controls at either 24 or 96 h post-exposure.
Apoptotic cells in the interstitium were also extremely rare
in both cisplatin-exposed and vehicle control tissues.
Therefore, we assessed proliferation (Ki67+) as an explan-
ation for germ cell population loss in cisplatin-exposed tes-
ticular tissues at 24 h post-exposure (Fig. 4a, b). At this
time-point, there were no significant differences in prolifer-
ation of either germ cell population following cisplatin-
exposure (Fig. 4c–e). However, at 96 h post-exposure
(Fig. 4f, g), there was a reduction in proliferating germ cells
Fig. 4 Acute effects of cisplatin exposure on germ cell proliferation in the human foetal testis. AP2γ+ gonocytes (red), MAGEA4+ (pre)-
spermatogonia (blue) and Ki67 (proliferation; green) protein expression in the human foetal testis 24 h (a, b) and 96 h (f, g) following exposure to
vehicle (VEH) or cisplatin (CIS; 0.5 μg/ml). Scale bars represent 100 μm (or 20 μm for insets). Quantification of germ cell counts per tubular area
(mm2) in the human foetal testis 24 h (c–e) and 96 h (h–j) following exposure to vehicle or cisplatin (0.5 μg/ml). A decrease in proliferating
(pre)spermatogonia and total germ cells was observed at 96 h post exposure to cisplatin. *p < 0.05, **p < 0.01. Data analysed using two-way
ANOVA. Values shown are means ± SEM and each set of coloured data points represents an individual foetus (n = 7)
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in cisplatin-exposed testicular tissues, compared with ve-
hicle controls (Fig. 4h–j). Proliferating (pre)spermatogonia
were significantly reduced (− 81%, 5 v 26, p < 0.01; Fig. 4i)
by cisplatin exposure, and whilst there was a similar trend
towards reduction in proliferating gonocytes (− 71%, 28 v
101, p = 0.06; Fig. 4e), this did not reach statistical signifi-
cance. Overall, proliferation was decreased in the total germ
cell population (− 70%, p < 0.05; Fig. 4j).
These data demonstrate acute and specific loss of germ
cells from the seminiferous epithelium of human foetal tes-
ticular tissues following cisplatin exposure. Furthermore,
there was a differential effect in the timing of germ cell loss,
with gonocyte number being reduced at an earlier time-
point (72 h) compared to (pre)spermatogonial number (96
h). This germ cell loss was associated with a reduction in
the number of proliferating germ cells in the testis.
Exposure to cisplatin results in long-term germ cell loss in
human foetal testis xenografts
To determine whether there is potential for recovery from
acute cisplatin-induced loss of germ cells, given the ongoing
albeit reduced rate of germ cell proliferation, human foetal
(n= 4) testicular tissue pieces that had been exposed to cis-
platin in vitro were xenografted subcutaneously into im-
munocompromised host mice for 12 weeks (Fig. 4). Graft
retrieval rates were similar for mice xenografted with
cisplatin-exposed testicular tissues compared with vehicle
controls (90 v 77%, p > 0.05). Seminiferous cord structure
was maintained and both germ cell populations were identi-
fied in vehicle (Fig. 5a) and cisplatin-exposed (Fig. 5b) xeno-
grafts. However, mean retrieved xenograft weights (mg)
were significantly reduced in the cisplatin-exposed group
compared with vehicle controls (− 50%, 0.50 v 1.02, p <
Fig. 5 Long-term effects of cisplatin exposure on human foetal testis xenografts. Immunohistochemistry for AP2γ+ gonocytes (red) and MAGEA4+
(pre)-spermatogonia (blue) in human foetal testis tissues exposed to vehicle (VEH; a) or cisplatin (CIS; b) for 24 h prior to xenografting (12 weeks).
Total graft weight (c) was significantly reduced following cisplatin-exposure. Quantification of cell number (d–f) and proliferation (g–i) of germ
cell populations per tubular area (mm2) in xenografts. A significant decrease in all germ cells populations was observed in cisplatin-exposed
tissues. Proliferating (pre)spermatogonia and total germ cells were also significantly reduced in cisplatin-exposed tissues after long-term
xenografting. Data analysed using two-way ANOVA. *p < 0.05, **p < 0.01 and ***p < 0.001. Values shown are means ± SEM and each set of
coloured data points represents an individual foetus (n = 4)
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0.001; Fig. 5c). Assessment of xenografts at 12 weeks post-
grafting revealed a significant reduction in gonocyte (− 68%,
37 v 115, p < 0.01; Fig. 5d), (pre)spermatogonial (− 35%, 238
v 366, p < 0.01; Fig. 5e) and total germ cell (− 42%, 276 v
475, p < 0.01; Fig. 5f) numbers in cisplatin-exposed xeno-
grafts compared with vehicle control xenografts. The reduc-
tion in graft weight and in total germ cell number in the
cisplatin-exposed group could result from either persistent
cell loss or a reduction in cell proliferation. Therefore, we
quantified proliferation in the germ cell sub-populations
(Fig. 5g–i). There was a significant reduction in proliferation
of (pre)spermatogonia (− 63%, 11 v 30, p < 0.05; Fig. 5h) and
total germ cells (− 59%, 27 v 65, p < 0.05; Fig. 5i); however,
the similar degree of reduction in gonocytes was not statisti-
cally significant (− 53%, 26 v 55, p > 0.05; Fig. 5g).
Taken together, these data indicate that cisplatin-
induced (pre)spermatogonial loss persists in the imma-
ture human testis for several months post-exposure and
that germ cell proliferation is not sufficiently increased
to compensate for this loss.
Cisplatin-exposure leads to loss of spermatogonial stem
cells in the human prepubertal testis
Spermatogonia in the prepubertal human testis have
been shown to express MAGEA4, with a sub-population
of spermatogonia co-expressing UTF1 believed to repre-
sent spermatogonial stem cells (SSCs) [7]. Given that fu-
ture fertility is dependent on the survival of the SSC
population, we interrogated our recent single-cell tran-
scriptomics data from prepubertal human testicular tis-
sues for MAGEA4 and UTF1 [7]. In tissues obtained
from a 7-year-old boy, germ cells were represented by a
distinct cluster separate from somatic cell populations
(Fig. 6a). MAGEA4 showed relatively stable expression
in germ cells of boys aged 1, 7 and 11 years, whilst rela-
tive expression of UTF1 was reduced with increasing age
(Fig. 6b), probably due to progression towards spermato-
gonial differentiation [7]. To determine whether
cisplatin-exposure in prepuberty results in a similar
germ cell (MAGEA4+) loss to that described for the hu-
man foetal testis and if this included the spermatogonial
stem cell (MAGEA4+ /UTF1+) population, we performed
in vitro culture of prepubertal testicular tissue obtained
from boys prior to chemotherapy exposure (n = 3–5, 1–
12 years). Tissues were exposed to cisplatin (0.5 μg/ml)
for 24 h, with analysis at 24 (n = 5, aged 1, 1, 8, 11 and
12 years) and 96 h (n = 3, aged 1, 1 and 12 years) post-
exposure (Fig. 6c–h). Cisplatin-exposure did not result
in a significant change in the total number of spermato-
gonia at 24 h post-exposure (536 v 496, p > 0.05; Fig. 6d).
Overall, SSC number was reduced in prepubertal human
testicular exposed to cisplatin at 24 h post-exposure,
compared to vehicle-exposed controls, although this was
not statistically significant (16 v 75, p > 0.05; Fig. 6e). As
there was sufficient testicular tissue available from three
of the patients (aged 1, 1 and 12 years), we also investi-
gated the effects of cisplatin treatment at 96 h post-
exposure. Quantification showed that there was a signifi-
cant reduction in total spermatogonial number (− 30%,
310 v 446, p < 0.05; Fig. 6G) and a reduction in SSC
number (− 52%, 6.5 v 13.5, p < 0.05; Fig. 6H), compared
to vehicle-exposed controls. Importantly, there were no
SSCs remaining in the cisplatin-exposed group for 2 out
of 3 patients (aged 1 and 12 years) (Fig. 6h).
In summary, these results demonstrate cisplatin-
induced germ cell loss in prepubertal human testicular
tissues, including a reduction or loss of the SSC popula-
tion. The degree and timing of spermatogonial cell loss
was similar to that seen in human foetal testicular tis-
sues after cisplatin exposure. This provides further valid-
ation for the use of the human foetal testis as a relevant
model system for studying impacts of exposures during
prepuberty, whilst also demonstrating consistent germ
cell effects at different key stages of human testicular
development.
Carboplatin induces similar effects to cisplatin on germ
cell populations in the human foetal testis
Carboplatin is used in clinical practice as an alternative
to cisplatin because of its reported lower risk of side ef-
fects. Therefore, we aimed to determine whether carbo-
platin exposure resulted in a reduction in gonadotoxicity
compared with cisplatin, at equivalent human-relevant
concentrations. Human foetal testicular tissues (n = 6)
were exposed in vitro to cisplatin (0.5 μg/ml), carbopla-
tin (5 μg/ml) or vehicle for 24 h: carboplatin was admin-
istered at 10 times the concentration to cisplatin in line
with relative therapeutic doses used in patients. Germ
cells were quantified at 72 and 240 h post-exposure
(Fig. 7). At 72 h post-exposure, there was a significant
reduction in gonocytes in cisplatin-exposed compared to
vehicle-exposed tissues (− 28%, 193 v 267, p < 0.01),
whilst carboplatin did not result in a significant change
in gonocyte number (Fig. 7a). (Pre)spermatogonia and
total germ cell number were unaffected after 72 h for
both platinum-based agents (Fig. 7b, c). However, at
240 h post-exposure, gonocytes were significantly re-
duced to a similar extent following exposure to cisplatin
(− 67%, 76 v 228, p < 0.0001) or carboplatin (− 58%, 96 v
228, p < 0.0001), compared with vehicle-exposed controls
(Fig. 7d). (Pre)spermatogonial numbers were similar be-
tween cisplatin- and carboplatin-exposed testicular tis-
sues after 240 h and were not significantly different to
vehicle controls (Fig. 7e). However, total germ cell num-
ber was significantly reduced by a similar amount in
both cisplatin- (− 30%, 492 v 704, p < 0.01) and
carboplatin-exposed tissues (− 28%, 509 v 704, p < 0.05)
compared to vehicle control (Fig. 7f).
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Taken together, these results demonstrate that
clinically equivalent exposure to carboplatin results
in similar effects on the germ cell population of the
immature human testicular tissues to those of
cisplatin.
Discussion
The present study, using validated experimental models,
demonstrates that exposure to platinum-based chemo-
therapy agents results in acute loss of germ cells in the
immature human testis and that this germ cell loss does
Fig. 6 Effects of cisplatin exposure on human prepubertal testis. a t-SNE plot of cell populations obtained during single-cell sequencing of
testicular tissue of a 7-year-old male. b Violin plots for normalised expression of (pre)spermatogonium (MAGEA4) and SSC (UTF1) populations in
testicular tissues from 1-, 7- and 11-year-old (yo) males. Red dots represent mean expression. Effect of cisplatin (CIS, 0.5 μg/ml) exposure on MAGE
A4+ spermatogonia (blue) and UTF1+ (green) SSCs in the human prepubertal testis 24 h (c–e) and 96 h (f–h) after exposure compared to vehicle
(VEH) control. A significant decrease in spermatogonia and SSCs was observed at 96 h post-cisplatin exposure. Data analysed using two-way
ANOVA. *p < 0.05. Values shown are means ± SEM and each set of coloured data points (blue and red—1 year, orange—8 years, green—11 years,
purple—12 years) represents an individual patient (n = 3–5). c, f Arrows—spermatogonium (MAGEA4+), arrowheads—SSC
subpopulation (MAGEA4+/UTF1+)
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not recover several months after exposure. The results
also indicate a differential decline in germ cell popula-
tions, involving an initial loss of gonocytes followed by a
reduction of spermatogonia. Importantly, the effects of
carboplatin were similar to those of cisplatin, based on
human-relevant drug concentrations.
Cisplatin exposure resulted in a significant reduction
in total germ cells in both foetal and prepubertal human
testicular tissues in culture. This is in keeping with a
previous in vitro study in rodents, which demonstrated a
reduction in germ cell number in prepubertal mouse tes-
ticular tissues exposed to cisplatin [17]. In that study,
there was a > 95% reduction in germ cell number 72 h
after cisplatin exposure, whereas the reduction in germ
cells in the present study was ~ 70–80% at 96 h post-
exposure.
A key finding from the present study was the reduc-
tion in the SSC pool in prepubertal human testicular tis-
sues following exposure to platinum-based
chemotherapy. SSCs represent the key population re-
quired for repopulation and restoration of spermatogen-
esis in the adult testis following gonadotoxic therapy in
primates [18]. Implementation of single-cell transcripto-
mics has allowed a detailed characterisation of sperm-
atogonial populations present within the adult human
testis [19, 20] and several SSC ‘states’ each with a unique
transcriptional profile have been described [19]. This ap-
proach has also been applied to the human prepubertal
testis, indicating the existence of similar SSC signatures,
including the expression of UTF1 as a key feature of the
SSC pool [7]. The present study demonstrates that ex-
posure to cisplatin in vitro results in a 52% reduction in
SSCs (MAGEA4+ /UTF1+) in the prepubertal human
testicular tissues. Importantly, this overall reduction in
SSCs includes 2 out of 3 patients (aged 1 and 12 years)
in whom no SSCs were identified in the tissue 96 h after
exposure. This suggests that fertility may be permanently
impaired in some individuals receiving therapeutic doses
of cisplatin, consistent with the association of cisplatin
exposure with infertility in male childhood cancer survi-
vors [4]. Further studies involving a larger number of pa-
tient samples are required to reduce the impact of
individual variability and determine whether SSC loss
following platinum-based chemotherapy is dependent on
age or pubertal status. The present findings are of poten-
tial importance for counselling patients on future fertility
and for fertility preservation options. Current strategies
to preserve fertility in prepubertal boys involve cryo-
preservation of testicular material [8, 21]. However, the
future success of this process to restore fertility later in
life is dependent on the preservation of germ cells with
stem cell capability of cryopreserved tissues [22]. It is
Fig. 7 Comparison of cisplatin and carboplatin exposure on germ cell populations of the human foetal testis. Quantification of germ cell
subpopulations in the human foetal testis 72 h (a–c) and 240 h (d–f) following exposure to vehicle (VEH), cisplatin (CIS; 0.5 μg/ml) or carboplatin
(CARBO; 5 μg/ml). At 72 h post-exposure, gonocytes were significantly reduced for cisplatin only. At 240 h post exposure, a decrease in gonocytes
and total germ cells was observed following exposure to either cisplatin or carboplatin. Data analysed using two-way ANOVA. *p < 0.05, **p < 0.01
and ****p < 0.0001. Values shown are means ± SEM and each set of data point represents an individual foetus (n = 6)
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conceivable that some of the surviving (MAGEA4+
/UTF1−) germ cells in these patients may retain, or ac-
quire, SSC capabilities following gonadotoxic therapy, as
has been demonstrated in mouse models of testicular re-
generation and repair following exposure to busulphan,
a chemotherapeutic belonging to the highly gonadotoxic
group of alkylating agents [23].
The impacts of exposure to chemotherapy during
childhood on subsequent reproductive function have
been investigated in clinical cohorts of childhood cancer
survivors [3–5, 24]. These studies demonstrate that ex-
posure to alkylating agents is associated with infertility in
males [5]. For cisplatin, the data is less consistent. Expos-
ure to platinum-based chemotherapy was not associated
with a reduction in partner pregnancy rates in one cohort
of childhood cancer survivors [25], whilst two other stud-
ies involving the Childhood Cancer Survivor Study re-
ported a significant reduction in partner pregnancy rates
in cancer survivors treated with platinum agents com-
pared to their siblings [4, 5]. Clinical studies involving
childhood cancer survivors are limited in their ability to
determine the effects of individual agents as they usually
involve individuals who have received a variety of treat-
ments, including combined therapies which result in series
of small numbers of patients receiving like-for-like treat-
ments. Therefore, studies involving human-relevant
experimental systems can be useful to determine the
specific effects of an individual agent on testicular
germ cells.
The search for effective cancer therapies with reduced
side-effects has prompted the development of new gen-
erations of drugs with lower cytotoxicity. Therefore, we
compared the relative gonadotoxicity of cisplatin with
carboplatin and showed that there were minimal differ-
ences in the impact on germ cell numbers between these
two platinum-based therapies. Exposure to either agent
resulted in a significant reduction in germ cell number
in human foetal testicular tissues with a similar degree
of germ cell loss in cisplatin- (− 34%) compared to
carboplatin-exposed (− 26%) testicular tissues at 240 h
post-exposure. Although the reduction in (pre)spermato-
gonial numbers in the cisplatin-exposed group did not
reach statistical significance, there was a similar magni-
tude of reduction to the initial cisplatin-exposure studies
and this is likely to be explained by the smaller number
of foetal testicular samples used in the cisplatin-
carboplatin studies. Importantly, the present work used
exposures that reflect differences in the doses given to
patients in clinical practice: carboplatin is given at ~ 10
times the dose of cisplatin and therefore the concentra-
tions used in our in vitro treatments reflected this differ-
ence. The finding of no difference in relative
gonadotoxicity between the two agents is consistent with
a recent study comparing in vitro exposure in
prepubertal murine testis [26]. This study demonstrated
a significant reduction in spermatogonia in both cis-
platin- and carboplatin-exposed testis when compared to
vehicle-exposed controls with an almost identical pro-
portion of germ cell loss for both drugs [26]. Whilst no
advantage of using carboplatin versus cisplatin is dem-
onstrated in relation to gonadotoxicity, the fact that
there is no worsening of testicular effects coupled with
reported advantages of carboplatin for reducing toxic-
ities in other organs (e.g. ototoxicity) may still support
the preferential use of carboplatin. Comparably, replace-
ment of the alkylating agent procarbazine with an alter-
native (dacarbazine) from the same class is associated
with an increased recovery of spermatogenesis without
affecting overall patient survival [27]. Overall, these re-
sults demonstrate the importance of establishing the
relative toxicity on each tissue of potential replacements
for current therapies, especially when the replacement is
in the same class as the existing agent. Because of the
limited availability of human material for research, the
analysis had to be performed across broad age groups,
ranging from ‘second trimester’ and ‘prepuberty’. Hence,
a larger study distinguishing early and late foetal and
specific prepubertal periods, e.g. ‘mini-puberty’ in early
postnatal life, may provide further insight into gonado-
toxic impacts on the testis at specific stages during
development.
This study demonstrates the utility of these novel ex-
perimental approaches for assessing the acute and long-
term effects of chemotherapy exposures on the human
prepubertal testicular tissues. In addition, the experi-
mental models may also be used to study the combin-
ation of treatments and repeated exposures to mimic
regimens used in clinical practice. This would provide
direct experimental evidence to complement the findings
from clinical studies involving male childhood cancer
survivors [5]. Cancer treatments are rapidly evolving to
include novel agents including immunotherapy involving
monoclonal antibodies and manipulation of specific cell-
signalling pathways. For many of these agents, there is
no information on long-term reproductive effects. The
presently used experimental test systems provide a
human-relevant model that can be used to investigate
the gonadotoxicity of these emerging cancer therapies.
The results of this study in relation to the sensitivity of
the gonocyte population are important and have impli-
cations for chemotherapy treatment given to pregnant
women. It is recognised that many chemotherapeutics
can induce foetal loss due to global toxicity to the
mother; however, when foetal loss is not expected, there
may still be effects on gonadal function and germ cell
survival of the developing foetal testis. During the first
trimester of pregnancy, the germ cell population in the
foetal gonad consists primarily of gonocytes [16]. During
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foetal life, there is a gradual transition of the entire germ
cell population from gonocyte to (pre)spermatogonia
[16, 28]. In the present study, the acute reduction of
gonocytes resulting from in vitro exposure to platinum-
based chemotherapy agents was associated with a subse-
quent reduction in (pre)spermatogonia in the human
foetal testis. This indicates that the establishment of the
spermatogonial population in the foetus may be sensitive
to the chemotherapy regimen given to the mother dur-
ing pregnancy. This is further supported by the finding
that the reduction in (pre)spermatogonial number is
maintained in xenografted testicular tissues several
months after exposure. We have previously shown that
human foetal testis xenografts exhibit good preservation
of testicular structure, seminiferous cord appearance and
histology compared with ungrafted materials and that
development from gonocytes to spermatogonia con-
tinues during the graft period, similar to age-matched
ungrafted control testis [16]. Hence, the xenograft model
represents a suitable system to determine the effects of
exposure on germ cells in the human foetal testis.
Few studies have investigated the effects of cisplatin
exposure in pregnancy. Cisplatin administered to preg-
nant women for cervical cancer during the second tri-
mester crosses the placenta resulting in concentrations
ranging from 23 to 65% (cord blood) and 11–42% (amni-
otic fluid), compared with those in the maternal circula-
tion [29]. In baboons, administration of carboplatin has
been shown to result in foetal serum levels which were
~ 50% of those in the maternal serum and significant
malformations were noted in 4% of the exposed foetuses
[30]. In rodents, cisplatin accumulated in foetal tissue
approximately a week post-administration [31]. Placental
transfer occurs through diffusion, although platinum
agents also commonly utilise active transport mediated
via transporters p-glycoprotein, multi-resistance protein
(MRP)-1 and 2 [32], copper influx transporters, ATP7A
and ATP7B [33].
Foetal life is a critical period for programming subse-
quent testicular development and reproductive function
[34]. Exposure to a variety of environmental agents and
pharmaceuticals during foetal life has previously been
shown to result in germ cell loss in rodents and humans
[35]. Recent studies have demonstrated that exposure to
human-relevant concentrations of acetaminophen (para-
cetamol) results in a reduction of gonocytes and total
germ cell number (including (pre)spermatogonia) in hu-
man foetal testicular tissues including acute effects of
in vitro exposure and in long-term xenografts [13]. The
gonocyte population was predominantly affected in the
present study as previously demonstrated for exposure
to phthalates [36]. The mechanism for the acute germ
cell loss following cisplatin exposure is likely to involve
direct damage to the germ cells. We investigated the
potential mechanism for cisplatin-induced reduction in
germ cell numbers. As previously reported, there is an
increase in apoptosis (expressed as percentage of tubules
stained with cleaved caspase 3) 8 h prior to the decrease
in germ cell number in cisplatin-treated prepubertal
mouse testicular tissues [17]. In contrast, the present
study suggests that there is no apparent difference in
apoptotic cell number at any time point studied. How-
ever, activation of cleaved caspase 3 pathway could
occur between 24 and 72 h post cisplatin exposure, be-
fore the reduction in germ cell number becomes appar-
ent. Interestingly, studies involving acetaminophen- or
phthalate-exposure have shown that testicular effects
may also involve the associated reduction in testosterone
during foetal life [13, 14, 37]. The impact of platinum-
based agents on somatic (including Leydig) cell function
in foetal and early postnatal testicular tissues requires
further investigation.
Early postnatal life is also another crucial period for
germ cell development and testicular growth [38]. The
hypothalamo-pituitary-gonadal axis is active and the
completion of gonocyte differentiation into spermato-
gonia occurs during this period [38]. As a result, gono-
cyte loss following platinum exposure during infancy
may impact on the establishment of the normal pool of
SSCs, and fertility in adulthood. This is of particular im-
portance for malignancies (e.g. neuroblastoma) that can
arise shortly after birth or during infancy.
Conclusion
In conclusion, we show that exposure to human-relevant
concentrations of platinum-based chemotherapy results
in a reduction in germ cell number, including spermato-
gonial stem cells, in the immature human testis. We ob-
served a similar germ cell loss for cisplatin and
carboplatin, suggesting that carboplatin may not have re-
duced gonadotoxicity compared to cisplatin. These ex-
perimental approaches using human tissues can be
broadly applied to determining the relative gonadotoxi-
city of current and novel cancer therapies, which is im-
portant for counselling, modification of treatment
regimens and developing strategies to preserve fertility
in children with cancer.
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tubule, (B) cell in the interstitium. There was no significant change in the
number of apoptotic cells within tubules at 24 h (C) and 96 h (D), and no
significant change in the number of apoptotic cells in the interstitium at
24 h (E) and 96 h (F) post-exposure to cisplatin. Data analysed using two-
way ANOVA. Values shown are means ± SEM and each set of coloured
data points represents an individual fetus (n = 5).
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